Methylnaltrexone and alvimopan: economic management of opioid-induced bowel dysfunction

References

• Miedema BW, Johnson JO. Methods for decreasing postoperative gut dysmotility. Lancet Oncol 4(6), 365–372 (2003).
   PubMed Web of Science ®Google Scholar
• Ahmedzai S, Brooks D. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy and quality of life. The ITS-Fentanyl Comparative Trial Group. Pain Symptom Manage. 13(5), 254–261 (1997).
   PubMed Web of Science ®Google Scholar
• Moss G, Regal ME, Lichtig L. Reducing postoperative pain, narcotics and length of hospitalization. Surgery 99(2), 206–210 (1986).
   PubMedGoogle Scholar
• Livingston EH, Passaro EP Jr. Postoperative ileus. Dig. Dis. Sci. 35(1), 121–132 (1990).
   Google Scholar
• Pappagallo M. Incidence, prevalence and management of opioid bowel dysfunction. Arn. j&iig. 182(Suppl. 5A), S11—S18 (2001).
   Google Scholar
• Vanegas G, Ripamonti C, Sbanotto A et al. Side effects of morphine administration in cancer patients. Cancer Nurs. 21(4), 289–297 (1998).
   Google Scholar
• Mancini I, Bruera E. Constipation in advanced cancer patients. Support Cate Cancer6(4), 356–364 (1998).
   PubMed Web of Science ®Google Scholar
• Allan L, Hays H, Jensen NH et al. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic noncancer pain. BE Med 322(7295), 1154–1158 (2001).
   PubMed Web of Science ®Google Scholar
• Lesage P, Portenoy RK. Trends in cancer pain management. Cancer Con. 6 (2), 136–145 (1999).
   Google Scholar
• Basse L, Madsen JL, Kehlet H. Normal gastrointestinal transit after colonic resection using epidural analgesia, enforced oral nutrition and laxative. BE J. Surg. 88(11), 1498–1500 (2001).
   Google Scholar
• Klepstad P, Kaasa S, Skauge M et al Pain intensity and side effects during titration of morphine to cancer patients using a fixed schedule dose escalation. Acta Anaesthesial. Scand. 44(6), 656–664 (2000).
   Google Scholar
• Fallon MT, Hanks GW. Morphine, constipation and performance status in advanced cancer patients. Pa/fiat. Merl 13(2), 159–160 (1999).
   Google Scholar
• Ioannides-Demos LL, Eckert GM, McLean AJ. Pharmacoeconomic consequences of measurement and modification of hospital drug use. PharmacoEconomics 2 (1), 15–33 (1992).
   PubMedGoogle Scholar
• Bates DW, Spell N, Cullen DJ et al The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. JAIVIA 277(4), 307–311(1007).
   Google Scholar
• Classen DC, Pestotnik SL, Evans RS et al. Adverse drug events in hospitalized patients. Excess length of stay, extra costs and attributable mortality. JAIVIA 277(4), 301–306 (1997).
   PubMedGoogle Scholar
• American Pain Society. Principles of Analgesic Use in the Treatment of Acute and Cancer Pain. Fourth Edition. American Pain Society, IL, USA (1999).
   Google Scholar
• Oderda GM, Evans RS, Lloyd J et al. Cost of opioid-related adverse drug events in surgical patients. j Pain Symptom Manage. 25(3), 276–283 (2003).
   Google Scholar
• •Addresses opioid-related adverse drug events. The authors conclude these are common problems in hospitalized patients and they increase length of stay and total hospital costs.
   Google Scholar
• Yuan CS, Foss JF, O'Connor M et al. Effects of enteric-coated methylnaltrexone in preventing opioid-induced delay in oral-cecal transit time. Clin. Pharmacol Ther. 4, 398–404 (2000).
   Google Scholar
• Taguchi A, Sharma N, Saleem RM et al. Selective postoperative inhibition of gastrointestinal opioid receptors. N Engl. J. Med. 345(13), 935–940 (2001).
   Google Scholar
• ••Shows the selective inhibition ofgastrointestinal opioid receptors by an antagonist with limited oral absorption that does not readily cross the blood—brain barrier, speeds recovery of bowel function and shortens the duration of hospitalization.
   Google Scholar
• White F, Watcha WE Pharmacoeconomics in anaesthesia: what are the issues? Eur. j Anaesthesia" Stipp" 23,10-15 (2001).
   Google Scholar
• Kehlet H, Mogensen T Hospital stay of 2 days after open sigmoidectomy with a multimodal rehabilitation programme. BE Surg. 86(2), 227–230 (1999).
   Google Scholar
• Basse L, Hjort JD, Billesbolle P et al. A clinical pathway to accelerate recovery after colonic resection. Ann. Surg. 232(1), 51–57 (2000).
   PubMed Web of Science ®Google Scholar
• •A multimodal rehabilitation is beneficial as it may significantly reduce the postoperative hospital stay in high-risk patients undergoing colonic resection. Such a program may also reduce postoperative ileus and cardiopulmonary complications. These results may have important implications in clinical practice.
   Google Scholar
• Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs 63(7), 649–671 (2003).
   PubMed Web of Science ®Google Scholar
• Handal IKA, Schauben JL, Salamone FR. Naloxone. Ann. Emerg. Med. 12 (7), 438–445 (1983).
   Google Scholar
• Culpepper-Morgan JA, Inturrisi CE, Portenoy RIK et al Treatment of opioid-induced constipation with oral naloxone: a pilot study. Clin. Pharmacol Ther. 52(1), 90–95 (1992).
   PubMedGoogle Scholar
• Sykes NP An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliat. Med. (2), 135–144 (1996).
   Google Scholar
• Meissner W, Schmidt U, Hartmann M et al Oral naloxone reverses opioid-associated constipation. Pain 84(1), 105–109 (2000).
   PubMed Web of Science ®Google Scholar
• Liu M, Wittbrodt E. Low-dose oral naloxone reverses opioid-induced constipation and analgesia. J. Pain Symptom Manage. 23(1), 48–53 (2002).
   PubMed Web of Science ®Google Scholar
• Cheskin LJ, Chami TN, Johnson RE et al Assessment of nalmefene glucuronide as a selective gut opioid antagonist. Dmg Alcohol Depend. 39(2), 151–154 (1995).
   Google Scholar
• Russell J, Bass P, Goldberg LI et al Antagonism of gut but not central effects of morphine with quaternary narcotic antagonists. Eur I Pharmacol 78(3), 255–261 (1982).
   PubMedGoogle Scholar
• Brown DR, Goldberg LI. The use of quaternary narcotic antagonists in opiate research. Neuropharmacology 24 (3), 181–191(1985).
   PubMed Web of Science ®Google Scholar
• Bianchi G, Fiocchi R, Tavani A et al Quaternary narcotic antagonists' relative ability to prevent antinociception and gastrointestinal transit inhibition in morphine-treated rats as an index of peripheral selectivity. Life Li. 30(22), 1875–1883 (1982).
   Google Scholar
• Foss JE A review of the potential role of methylnaltrexone in opioid bowel dysfunction. Am. J. Surg. 182 (Suppl. 5A), S19—S26 (2001).
   Google Scholar
• Kotake AN, Kuwahara SK, Burton E et al Variations in demethylation of N-methylnaltrexone in mice, rats, dogs and humans. Xenobiotica 19 (11), 1247–1254 (1989).
   PubMed Web of Science ®Google Scholar
• Gmerek DE, Cowan A, Woods JH. Independent central and peripheral mediation of morphine-induced inhibition of gastrointestinal transit in rats. J. Pharmacol Exp. Ther 236(1), 8–13 (1986).
   Google Scholar
• Yuan CS, Foss JF, Moss J. Effects of methylnaltrexone on morphine-induced inhibition of contraction in isolated guineapig ileum and human intestine. Eur I Pharmacol 276(1-2), 107–111 (1995).
   PubMedGoogle Scholar
• Yuan CS, Foss JF, O'Connor M et al Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: a double-blind randomized placebo-controlled trial. Clin. Pharmacol Ther. 59(4), 469–475 (1996).
   PubMedGoogle Scholar
• Yuan CS, Foss JF, Osinski J et al The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time. Clin. Pharmacol Ther. 61(4), 467–475 (1997).
   PubMed Web of Science ®Google Scholar
• Yuan CS, Foss JF, O'Connor M et al Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial. JA/11/4 283(3), 367–372 (2000).
   Google Scholar
• ••Intravenous methylnaltrexone can inducelaxation and reverse the slowing of oral cecal-transit time in subjects taking high opioid dosages. This well-designed randomized controlled trial shows that low-dosage methylnaltrexone may have clinical utility in managing opioid-induced constipation.
   Google Scholar
• Zimmerman DM, Gidda JS, Cantrell BE et al Discovery of a potent, peripherally selective trans-3,4-dimethyl 4 (3 hydroxyphenyOpiperidine opioid antagonist for the treatment of gastrointestinal motility disorders. J. Med. Chem. 37(15), 2262–2265 (1994).
   Google Scholar
• Schmidt WK. Alvimopan (ADL 8–2698) is a novel peripheral opioid antagonist. Am. J. Surg: 182 (Suppl. 5A), S27—S38 (2001).
   Google Scholar
• Liu SS, Hodgson PS, Carpenter RL et al ADL 8–2698, a trans-3,4-dimethy1-4- (3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous morphine without affecting analgesia. Clin. Pharmacol Ther. 69(1), 66–71 (2001).
   Google Scholar